1	Factors associated with the uptake of Intermittent Preventive Treatment (IPTp-SP) for
2	malaria in pregnancy: further analysis of the 2018 Nigeria Demographic and Health Survey.
3	Godwin Okeke Kalu <sup>1*</sup> , Joel M Francis <sup>2¶</sup> , Latifat Ibisomi <sup>1,3</sup> , Tobias Chirwa <sup>1</sup> , Juliana Kagura <sup>1¶</sup>
4	<sup>1</sup> School of Public Health, Faculty of Health Sciences, University of the Witwatersrand,
5	Johannesburg, Gauteng, South Africa
6	<sup>2</sup> Department of Family Medicine and Primary care, School of Clinical Science, Faculty of Health
7	Sciences, University of the Witwatersrand, Johannesburg, Gauteng, South Africa
8	<sup>3</sup> Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria
9	*Corresponding author
10	Email: <u>chinwemerikalu@gmail.com</u> (GOK)
11	<sup>¶</sup> These authors contributed equally to this work
12	
13	
14	
15	
16	
17	

## 18 Abstract

Pregnancy-associated malaria is preventable and curable with intermittent preventive treatment 19 with Sulfodoxine-Pyrimethamine (IPTp-SP). However, despite the effectiveness of IPTp-SP 20 against malaria in pregnancy, the uptake among pregnant women in Nigeria remains very low. 21 22 Thus, this study aimed to establish the factors associated with the uptake of at least one dose and 23 optimal doses of IPTp-SP among pregnant women aged 15 to 49 years living in Nigeria in 2018. The study included 12,742 women aged 15 to 49 years with live births two years before or during 24 25 the 2018 Nigeria Demographic Health Survey (NDHS) in the analysis. Descriptive analysis was 26 carried out to determine the prevalence of IPTp-SP uptake. Multivariable logistic regression was 27 used to establish the factors associated with receiving IPTp-SP during pregnancy, adjusting for 28 possible confounding factors. Given the complex survey design, all analyses adjusted for sampling 29 weight, stratification and clustering. The p-value of <0.05 was considered significant. In 2018, 30 the prevalence of at least one dose of IPTp-SP was 63.6% (95% CI:62.0-65.1), and optimal doses 31 of IPTp-SP were 16.8% (95% CI:15.8–17.8) during pregnancy. After the multivariable analysis, age group, region, frequency of ANC visits, belief in IPTp-SP effectiveness, and morbidity caused 32 by malaria predicted the uptake of at least one IPTp-SP dose. Similar maternal characteristics, 33 including household wealth index, spouse's educational level and media exposure, were 34 significantly associated with taking optimal IPTp-SP doses. For instance, women in the wealthiest 35 36 households whose husbands had secondary education predicted a four-fold increase in uptake of at least one IPTp-SP dose (aOR:4.17; 95% CI:1.11-8.85). 37

The low prevalence and regional variations of IPTp-SP uptake in the study area imply that most pregnant women in Nigeria are at substantial risk of pregnancy-associated malaria. Therefore,

- stakeholders should explore context-specific strategies to improve the IPTp-SP coverage across
- the regions in Nigeria.
- Keywords: Pregnancy-associated malaria, Intermittent preventive treatment, Sulfadoxine-
- Pyrimethamine, Antenatal care, Malaria morbidity, Nigeria

# 64 Introduction

65 Over the past two decades, about 1.7 billion malaria cases and 10.6 million malaria-related deaths were averted (1). Also, malaria mortality rates, that is, deaths per 100,000 population at risk, 66 declined from 25 in 2000 to 12 in 2015 and 10 in 2019, globally (2). Equally, the estimated number 67 68 of deaths decreased from 896,000 in 2000 to 558,000 in 2019 (2,3). However, , in 2020, malaria 69 deaths increased to 627,000, partially due to disruptions of malaria services during the COVID-19 70 pandemic. In 2020, the WHO African region accounted for 95% of the 241 million cases and 94% 71 of the global malaria deaths with four countries accounting for almost half of the global malaria 72 deaths (2). These four countries are Nigeria (31.9%), the Democratic Republic of the Congo (13.2%), United Republic of Tanzania (4.1%), and Mozambique (3.8%) (2). Nonetheless, young 73 74 children and pregnant women remain at significant risk of malaria infections. In 2019, 35% (12 75 million) of the estimated 33 million pregnant women living across 33 countries in the WHO African region were exposed to malaria infections during pregnancy (2). In the same year, the 76 exposure to malaria infections during pregnancies resulted to 822,000 children born with low 77 birthweight in these 33 countries (2) 78

79 In addition, approximately 50 million pregnant women remains at significant risk of pregnancyassociated malaria and possible malaria-related death annually (4). The risk associated with 80 malaria in pregnancy can be drastically reduced by using Intermittent Preventive Treatment with 81 Sulphadoxine-Pyrimethamine (IPTp-SP) for pregnancy-associated malaria as part of a multilevel 82 three-staged approach (5). IPTp-SP utilisation among pregnant women has contributed to nearly 83 42% decrease in low birth weight, 38% decrease in neonatal death, and 65% decrease in placental 84 malaria in SSA countries (1,6). However, full benefits are evident when pregnant women receive 85 three or more IPTp-SP doses (6). Receiving optimal IPTp-SP doses during pregnancy has 86

87 increased the mean birth weight, reduced low birth weight, and fewer placental malaria than taking most two doses (6). The WHO revised IPTp-SP guidelines in 2012 to increase the number of 88 Sulphadoxine-Pyrimethamine (SP) doses taken by pregnant women (5). Prior to 2012, the policy 89 90 proposed that IPTp-SP should be given to pregnant women at every ANC visit to ensure they receive at least two SP doses whereas the revised policy recommends all pregnant women should 91 92 receive one SP dose at every scheduled ANC visit except during first trimester at a one-month interval between each SP dose until time of delivery (5). Nigeria adopted the new IPTp-SP 93 guideline in 2014 for preventing or treating malaria or asymptomatic malaria infection during 94 95 pregnancy (7).

Despite the efforts by the WHO to increase the coverage of IPTp-SP in sub-Saharan African 96 97 countries, several maternal characteristics have been established as a barrier to IPTp-SP uptake during pregnancy. Studies have reported that pregnant women's attitudes and motivation to receive 98 IPTp-SP was related to their levels of knowledge of malaria-related factors such as morbidities 99 caused by malaria (8,9). Similarly, region, religion, age, and marital status influenced the number 100 IPTp-SP doses received during pregnancy (8,10,11). Socioeconomic considerations including 101 education level, spouse's education level, employment status, health insurance coverage and 102 103 household wealth index influenced IPTp-SP uptake (12,13). Increased uptake during pregnancy was associated with higher education (14,15), and some studies found a strong association between 104 105 being employed and IPTp-SP uptake (16). Also, several studies established that IPTp-SP uptake 106 was pro-rich, such that women in the "middle" to "richest" household wealth index had higher IPTp-SP uptake compared to those in the "poorest" to "poorer" wealth categories, including uptake 107 108 of at least three IPTp-SP doses during pregnancy (10,11,17,18).

109	The prevalence of at least one SP dose in Nigeria has increased from 27% in 2013 to 51% in 2015
110	and about 64% in 2018 (19). However, despite the relatively high prevalence of taking at least one
111	dose of SP by pregnant women in Nigeria , the gap between uptake of the first dose of the
112	antimalaria drug and at least three doses remains significantly large . For example, in 2018, the
113	prevalence of at least one dose was 64% compared to the about 17% prevalence of three or more
114	IPTp-SP doses (optimal doses) (19). This study examines the prevalence of IPTp-SP among
115	pregnant women and factors associated with the uptake of at least one dose and three or more doses
116	of IPTp-SP using the 2018 Nigeria Demographic Health Survey (NDHS).
117	
118	
119	
120	
121	
122	
123	
124	
125	
126	

## 127 Methods

## 128 Study design and study setting

The primary study; the Nigeria Demographic Health Survey women's data, was a cross-sectional 129 130 study conducted to provide estimates of the Nigerian populace's basic demographic and health indicators. The survey included samples from 36 States, including the Federal Territory Capital 131 (FCT). The sampling frame of the NDHS relied on the National Population and Housing Census 132 (NPHC) carried out in 2006. Two sampling stages were carried out, and each of the 36 states and 133 the Federal Capital Territory (FCT) were grouped into urban and rural areas to form 74 strata (19). 134 First, 1389 census enumeration areas (EAs) were chosen from 74 strata using probability 135 proportional to EA size as clusters independently. Secondly, 30 households were randomly 136 selected without replacement from each cluster to form a sample size of 41,666 households. 137 138 Weighting accurately represented the population during the NDHS dataset analysis due to the unequal distributed samples across each state and the potential disparity in the response rates. A 139 total of 42,121 women, 15 to 49 years old, was scheduled for an interview, and 41,821 women 140 were successfully interviewed (99% response rate). All women of childbearing age, between 15 to 141 49 years old, either resident in the selected household or female guests available in the households 142 a night before 14 August to 29 December 2018, were eligible and interviewed. A detailed 143 methodology for the 2018 NDHS has been published elsewhere (19). 144

145

## 147 Study population

The study population were all women aged 15 to 49 years who had live births during or two years before the survey resident in Nigeria between 2016 and 2018. This study involved the secondary data analysis of the data obtained from the NDHS Women dataset collected between August to December 2018.

## 152 Sampling and sample size

153 From the survey sampling frame, 41,821 women of childbearing ages (15 to 49 years ) were

interviewed. Among these women, 12,935 had livebirths during or two years preceding the 2018

155 NDHS. Of these, 12,742 women were extracted who reported to have received and known the

exact number of IPTp-SP doses they took during their last pregnancy. These 12,742 women served

as the analysis sample for this study after the survey weighting was applied (Fig 1).

#### 158 Fig 1: The Flow chart of the sample included in the NDHS 2018

159

160

161

162

163

164

165

166 167

168

169

# 171 Study variables

- 172 The extraction and coding of variables from the 2018 NDHS women dataset for the analysis were
- 173 guided by previous literature (20,21), and presented in <u>Table 1</u>.

174	Table 1: Categories and op	perational definitions of	selected exposure variables

Exposure variables	Definitions/Categories
Age in years	Age of the respondent during the 2018 NDHS (15-24, 25-
	34, 35+)
Marital status	Unmarried (singles and formerly married; widows and
	divorced) and married, including co-habiting
Household wealth Index	Economic/wealth status of respondents' household (Poorest,
	poorer, middle class, richer, richest)
<b>Region or Geopolitical zone</b>	This is region or geopolitical zone where a respondent reside
	in Nigeria (North Central, North East, North West, South
	East, South South, South West)
Residential areas	This is the area of residence of respondents (urban, rural)
Highest Educational Levels	Respondent's formal level of education (such as; none,
	primary level, secondary level, higher level)
Employment status	This is respondent's employment status (Not employed,
	employed)
Spouse's Education Level	This is the formal education level of respondent's spouse or
	partner (none, primary, secondary, higher level)
Frequency of ANC Visits	This is the number times a respondent visited antenatal care
	(ANC) clinic during pregnancy (None, less than 4 visits, 4+
	visits)
ANC Initiation	The trimester a respondent commenced antimalaria
	treatment (IPTp-SP) during pregnancy (1st Trimester, 2nd
	trimester, 3rd trimester)
Number of children born	Total number children even born (Less than four children,
	four or more children)
Belief in the effectiveness of IPTp-SP	Respondent's belief or trust in the efficacy of IPTp_SP to
	protect them and their fetus against malaria infection during
	pregnancy (Low, Average, high)
Belief about Malaria morbidity	Respondent's belief or awareness of the morbidity caused
	by malaria in pregnancy (Low, Average, High)
Health Insurance Coverage	Respondent who subscribed to any form of health insurance
	(yes, no)
Exposed to media messages	This was generated from whether a respondent used any of
	newspaper/magazine, radio or television (yes, no)

#### 176 **Outcome variables**

177 The outcome variables are the uptake of at least one dose of IPTp-SP and optimal doses of IPTp-178 SP during pregnancy. The outcomes were created using responses from the following two NDHS 179 survey questions (19): "did you take SP/Fansidar to prevent you from getting malaria during pregnancy? and how many times did you receive SP/Fansidar during this pregnancy?" For 180 181 statistical analysis, the uptake of at least one dose of IPTp-SP was categorised and coded into 0 182 = no dose of IPTp-SP and 1 = at least one dose of IPTp-SP ( $\geq 1$  dose). The uptake of optimal doses of IPTp-SP was categorised and coded into 0 = two or fewer doses ( $\leq 2$  doses) and 1 = at least 183 184 three doses of IPTp-SP ( $\geq$  3 doses) (10,21)

#### 185 **Exposure variables**

186 The extracted exposure variables were sub-grouped into the following factors empirically or theoretically associated with uptake of IPTp-SP: sociodemographic, pregnancy-related, and 187 knowledge of malaria-related factors. Sociodemographic factors include residential areas, age in 188 years, household wealth index, the highest level of education, region, religion, employment and 189 spouse's educational attainment. Pregnancy-related factors include frequency of ANC visits, the 190 timing of first ANC initiation, and parity. In addition, knowledge of malaria-related factors 191 includes belief in the effectiveness of IPTp-SP, belief about malaria consequences, subscription to 192 health insurance and media exposure. The household wealth index was derived in the primary 193 194 study (NDHS 2018) by scoring each number and asset owned by the selected households using principal component analysis (PCA). The assets ranged from a television to a bicycle or car and 195 housing characteristics such as the source of drinking water, toilet facilities, and flooring materials. 196 197 Then, the National wealth quintiles or index compiled by allocating the household score to each

usual (de jure) household resident. Subsequently, each 20% of the household population wasdivided into five equal categories from poorest to richest. (19).

200 The score for the level of belief in the effectiveness of IPTp-SP and malaria morbidity was 201 generated using a three-point Likert scale (22). The level of belief score about the effectiveness of IPTp-SP from two survey questions (19): "does malaria preventive medicine keep the mother 202 203 healthy?" "Does malaria preventive medicine keep the baby healthy?" Also, the level of belief score about malaria morbidity was derived from the following four survey questions (19): "can 204 malaria lead to death?" "can malaria make people dangerously sick?" "only weak children die 205 of malaria?" "Do not worry about malaria can be cured?" The women's responses to the 206 abovementioned questions asked in the Nigeria DHS were scored using a three-point Likert scale 207 such that 1 = Disagree, 2 = Do not know, and 3 = Agree (22). After that, row mean scores were 208 calculated for the women's array of responses to these questions using the "egen" command on 209 210 STATA. A score of one was the least possible score, and three was the highest possible score. 211 Finally, the terciles of the composite scores were used as a cut-off to categorise the level of belief scores into low (1.0 - 1.9), average (2.0) and high scores (2.1 - 3.0). 212

#### **Data management and analysis**

Data extraction, cleaning, re-coding and analysis were done using Stata version 16 (23). The extracted data were restricted to only women with live births during or two years before the 2018 NDHS. However, in creating the outcome variable, women who did not know if they took SP/Fansidar and the number of doses of SP/Fansidar taken was dropped, that is, 171 and 127 women, respectively. All selected exposure variables were categorical, and the missing observations across the exposure variables were reported as missing responses. Finally, the cleaned dataset was saved independently and converted into a survey dataset by applying the weighting,

stratification and clustering. Proportions and frequencies were used to summarise all categorical
variables for the descriptive analysis. At the same time, bivariate and multivariable logistic
regression were used in the analytical analysis. The bivariate and multivariable logistic regression
models were fitted using a four-step approach for modelling survey data as Heeringa et al., 2017
(59) and Hosmer and Lemeshow 2000 (60) recommended. The four-step approach is detailed
below:

227 First, we fitted a bivariate logistic regression model to estimate the association of the outcome 228 variables (at least one dose and optimal uptake) to each exposure variable. Second, all exposure 229 variables with a p-value of <0.10 from the bivariate models were selected as candidates for main effects in the multivariable logistic regression model. Building the final multivariable logistic 230 231 regression model involved an iterative process-the exposure variables of importance identified by previous studies were arranged from highest to the least importance. Third, fitted different 232 model specifications by manually adding or dropping each exposure variable by performing the 233 adjusted Wald test to assess each exposure variable's contribution to the model. Lastly, 234 scientifically plausible interactions among the exposure variables were checked. The interaction 235 term was assessed by specifying factorial interaction using binary operators (##). The selection of 236 237 the variables to interact was based on epidemiological notions or from previous literature. However, the selected multivariable logistic regression model accounted for only interaction terms 238 239 with a p-value < 5%. Then, the fit of the final model was assessed using the Hosmer-Lemeshow 240 goodness-of-fit test. The final models estimated the adjusted odds ratios (aORs). The significance level used was less than 5% (<0.05), two-tailed at 95% confidence intervals. 241

# 242 Ethical consideration

243	The Nigeria DHS 2018 was conducted by the Nigerian Population Commission in collaboration
244	with the National Malaria Elimination Programme (NMEP) of the Federal Ministry of Health,
245	Nigeria. Before each interview during the 2018 NDHS survey, all respondents above 18 years
246	provided written informed consent, and for those under 18 years of age written informed consent
247	was obtained from the parent/guardian. The fieldworker ensured confidentiality throughout the
248	survey process. The respondents' records were coded and de-identified (19). For this study,
249	permission for NDHS 2018 dataset for secondary data analysis has been obtained from ICF
250	International - Measure DHS website. Ethics approval was obtained from the University of the
251	Witwatersrand Human Research Ethics Committee (Medical) – M2011103.
252	
253	
254	
255	
256	
257	
258	

# 260 **Results**

#### 261 General characteristics of study participants

The study included 12,742 pregnant women between 15 and 49 years with live births from the 262 263 2018 NDHS. The mean age was  $28.3 \pm 6.7$  years old. The study participants were selected from all the six regions (geo-political zones) in varying proportions. Of which majority of them were 264 lived in Northwest Nigeria. 12,180 (95.6%) were married or living with a man, while 561 (4.4%) 265 were single, divorced or widows. Of these women, 6692 (52.7%) had less than four children, 266 whereas 6049 (47.5%) had four or more children. Also, more than half of the women, 7888 267 (61.9%), resided in rural Nigeria. In addition, the distribution of study participants varied 268 depending on maternal characteristics, 5,766 (45.3%) of study participants had no formal 269 270 education, and 4568 (35.9%) of them had husbands/spouses with no formal education. Although 271 8827 (69.3%) of the study participants were gainfully employed, only 2.0% subscribed to health insurance coverage. Additionally, 75.8% of them attended ANC services during pregnancy, of 272 which 56.1% visited the ANC clinic more than four times in 2018. In the same year, almost half 273 274 (47.1%) of the study participants initiated ANC services in their second trimester. Details of the characteristics of the study participants are presented in Table 2. 275

276

277

278

279

280

281

282

284	Table 2: Study characteristics of pregnant women aged 15 to 49 years old
-----	--

Characteristics	Categories	Frequency N(%)
Total		12,742 (100%)
So	ciodemographic characteristics	
Age in years	15-24	3842 (30.2)
Mean age: 28.3 years old	25-34	6242 (49.0)
Standard deviation: 6.7 years	35+	2657 (20.9)
Marital status	Unmarried	561 (4.4)
	Married	12,180 (95.6)
Household wealth Index	Poorest	2,763 (21.7)
	Poorer	2,933 (23.0)
	Middle	2,636 (20.7)
	Richer	2,358 (18.5)
	Richest	2052 (16.1)
Region	North Central	1,770 (13.9)
C	North East	2,339 (18.4)
	North West	4,638 (36.4)
	South East	1,263 (9.9)
	South-South	1,126 (8.8)
	South West	1,606 (12.6)
Residential areas	urban	4,854 (38.1)
	rural	7,888 (61.9)
Highest Educational Levels	No Education	5,766 (45.3)
	Primary	1,856 (14.6)
	Secondary	4,050 (31.8)
	Higher	1,070 (8.4)
Employment status	Not Employed	3,915 (30.7)
F-09	Employed	8,827 (69.3)
Spouse's Education Level	No Education	4,568 (35.9)
	Primary	1,624 (12.7)
	Secondary	4,116 (32.7)
	Higher	1,873 (14.7)
	Missing	561 (4.4)
Pr	regnancy-related characteristics	
Frequency of ANC Visits	No ANC Visit	3,081 (24.2)
1	< 4 ANC Visits	2,350 (18.4)
	≥4 ANC Visits	7,151 (56.1)
	Missing Response	160 (1.3)
ANC Initiation	1 st Trimester	2,273 (17.8)
	2nd Trimester	6,003 (47.1)
	3rd Trimester	1,366 (10.7)
	Missing	3,100 (24.3)
Number of children born	Less than four children	6692 (52.7)
	Four or more children	6049 (47.5)

Belief in Effectiveness of IPTp-SP	Low	200 (1.6)
-	Average	504 (4.0)
	High	12,038 (94.5)
Belief about Malaria morbidity	Low	1,614 (12.7)
	Average	3,869 (30.4)
	High	7,259 (57.0)
Health Insurance Coverage	No	12,484 (98.0)
	Yes	258 (2.0)
Exposed to media messages	No	11,823 (92.8)
	Yes	919 (7.2)

#### **Prevalence of IPTp-SP uptake among pregnant women in 2018**

306 The estimated prevalence of at least one IPTp-SP dose was 63.6% (95% CI: 62.0–65.1), and three 307 or more IPTp-SP doses were 16.8% (95% CI:15.9–17.8) among pregnant women in Nigeria (Table 308 3). Yet, the prevalence varied significantly depending on the maternal characteristics except for 309 marital status. For instance, the prevalence of at least one SP was highest among women aged 25 310 to 34 years at 64.9% (95% CI: 63.0 - 66.7). Similarly, women aged 25 to 34 also reported the 311 highest uptake of three or more SP doses at 17.7% (95% CI: 16.5–19.0). The result indicated that the higher the educational attainment among women, the higher the number of IPTp-SP doses 312 313 received during pregnancy. Also, among pregnant women, the number of IPTp-SP doses received 314 during pregnancy increased depending on their spouse's educational level. Likewise, there was an 315 increasing prevalence of SP doses among pregnant women from the poorest to the wealthiest 316 household wealth index (p < 0.001). The result also established that the frequency of ANC visits was directly related to the number of SP doses they take during pregnancy (p < 0.001). The 317 318 prevalence of at least one IPTp-SP dose at 80.3% (95% CI: 78.8 – 81.7) as well as the prevalence 319 of optimal SP doses at 23.3% (95% CI: 22.0 - 24.6) was the highest uptake was highest for those 320 who attended more than four ANC visits during pregnancy. Also, early initiation of antenatal care was related to a higher prevalence of at least one dose and optimal doses of SP (p < 0.001). The 321 prevalence of taking at least one dose and optimal SP doses was significantly related to the belief 322 323 in the effectiveness of IPTp-SP for protection against malaria in pregnancy (p < 0.001). In addition, 324 the prevalence of at least one IPTp-SP dose differed based on the level of belief about morbidities 325 caused by malaria (p < 0.001) but not the prevalence of taking optimal SP doses (p=0.242).

Factors	Total N (%)	% Women w	ho received $\geq 1$	p-value	% Women who received $\geq 3$		p-value
		dose			Doses		-
		$n^{a}$ (%)	95% CI		n <sup>b</sup> (%)	95% CI	
Uptake of SP dose	12742 (100%)	8098 (63.6)	62.0 - 65.1		2143 (16.8)	15.9 – 17.8	
Age in years				0.015*			0.010*
15-24	3842 (30.2)	2352 (61.2)	58.8-63.6		578 (15.0)	13.6 - 16.6	
25-34	6242 (49.0)	4049 (64.9)	63.0 - 66.7		1103 (17.7)	16.5 - 19.0	
35+	2657 (20.9)	1697 (63.9)	61.3 - 66.7		462 (17.4)	15.7 - 19.3	
Region				< 0.001*			< 0.001*
North Central	1770 (13.9)	1003 (56.7)	53.2 - 60.1		264 (14.9)	13.1 - 17.0	
North East	2339 (18.4)	1520 (65.0)	61.8 - 68.0		329 (14.1)	12.1 - 16.3	
North West	4939 (36.4)	2712 (58.5)	55.1 - 61.7		503 (10.8)	9.4 - 12.4	
South East	1263 (9.9)	1003 (79.5)	76.4 - 82.2		493 (39.1)	35.9 - 42.3	
South South	1129 (8.8)	837 (74.3)	71.6 - 76.9		275 (24.4)	21.6 - 27.6	
South West	1606 (12.6)	1023 (62.7)	59.9 - 67.3		279 (17.4)	14.6 - 20.5	
Residential areas				< 0.001*			< 0.001*
Urban	4853 (38.1)	3524 (72.6)	70.4 - 74.7		1032 (21.3)	19.6 - 23.0	
Rural	7888 (61.9)	4574 (58.0)	55.9 - 60.1		1112 (14.1)	13.0 - 15.3	
Marital status				0.980			0.753
Unmarried	561 (4.4)	357 (63.6)	59.0 - 68.0		98 (17.4)	14.1 - 21.3	
Married	12,180 (95.6)	7741 (63.6)	61.9 - 65.2		2046 (16.8)	15.8 - 17.9	
Highest Educational level				<0.001*			<0.001*
No Education	5766 (45.3)	2953 (51.2)	48.7 - 53.7		597 (10.4)	9.3 - 11.6	
Primary	1856 (14.6)	1259 (67.8)	65.2 - 70.4		340 (18.3)	16.4 - 20.4	
Secondary	4050 (31.8)	3008 (74.3)	72.5 - 75.9		938 (23.2)	21.6 - 24.9	
Higher	1070 (8.4)	878 (82.1)	79.2 - 84.7		268 (25.0)	21.7 - 28.8	
Household Wealth Index				< 0.001*			< 0.001*
Poorest	2763 (21.7)	1325 (47.9)	44.8 - 51.1		335 (12.1)	10.5 - 14.0	
Poorer	2933 (23.0)	1593 (54.3)	51.2 - 57.4		323 (11.0)	9.6 - 12.6	

# 326Table 3: Prevalence of IPTp-SP dose received by pregnant women aged 15 to 49 years in 2018

Middle	2636 (20.7)	1793 (68.0)	65.7 - 70.3		423 (16.1)	14.3 - 18.0	
Richer	2358 (18.5)	1728 (73.3)	70.7 - 75.7		550 (23.3)	21.0 - 25.9	
Richest	2052 (16.1)	1659 (80.8)	78.3 - 83.2		512 (24.9)	22.3 - 27.8	
Employment Status				< 0.001*			< 0.001*
Not Employed	3915 (30.7)	2247 (57.4)	54.8 - 60.0		539 (13.8)	12.3 - 15.4	
Employed	8827 (69.3)	5851 (66.3)	64.7 - 67.9		1604 (18.2)	17.1 - 19.3	
Spouse's Educational Level				<0.001*			< 0.001*
No Education	4568 (35.9)	2160 (47.3)	44.6 - 47.0		392 (8.6)	7.4 – 9.9	
Primary	1624 (12.7)	1058 (65.2)	62.1 - 68.2		248 (15.3)	13.3 - 17.5	
Secondary	4116 (32.7)	3020 (73.4)	71.6 - 75.1		974 (23.7)	22.0-25.4	
Higher	1872 (14.7)	1502 (80.3)	77.9 - 82.5		431 (23.0)	20.5 - 25.8	
Missing Response	561 (4.4)						
Frequency of ANC Visits				<0.001*			<0.001*
No ANC Visit	3081 (24.1)	508 (16.5)	14.7 – 18.5		134 (4.4)	3.4 - 5.5	
<4 ANC Visits	2350 (18.4)	1717 (73.1)	70.7 - 75.3		297 (12.6)	11.0 - 14.4	
$\geq$ 4 ANC Visits	7151 (56.1)	5739 (80.3)	78.8 - 81.7		1667 (23.3)	22.0 - 24.6	
Missing Response	160 (1.3)						
Timing of ANC initiation				<0.001*			<0.001*
1st Trimester	2273 (17.8)	1813 (79.8)	77.5 - 81.9		640 (28.2)	25.8 - 30.6	
2nd Trimester	6003 (47.1)	4752 (79.2)	77.6 - 80.7		1177 (19.6)	18.3 - 21.0	
3rd Trimester	1365 (10.7)	1007 (73.8)	70.9 - 76.5		186 (13.6)	11.5 – 16.1	
Missing Response	3100 (24.3)						
Number of children born				<0.001*			<0.001*
Less than 4 children	6692 (52.7)	4438 (66.3)	64.6 - 68.0		1226 (18.3)	17.1 – 19.6	
Four or more children	6049 (47.5)	3660 (60.5)	58.4 - 62.5		917 (15.2)	14.0 - 16.4	
Media Exposure				<0.001*			<0.001*
No	11822 (92.8)	7349 (62.2)	60.5 - 63.8		1855 (15.7)	14.8 - 16.7	
Yes	919 (7.2)	749 (81.5)	78.1 - 84.6		288 (31.3)	26.9 - 36.2	
Health Insurance coverage				0.001*			<0.001*
No	12484 (98.0)	7889 (63.2)	61.6 - 64.8		2072 (16.6)	15.6 - 17.6	
Yes	257 (2.0)	209 (81.2)	71.6 - 88.0		72 (27.8)	21.9 - 34.6	

Belief in Effectiveness of SP				< 0.001*			<0.001*
Low level of belief	200 (1.6)	86 (43.0)	35.7 - 50.7		14 (7.2)	4.5 - 11.4	
Average level of belief	504 (4.0)	174 (34.4)	28.6-40.7		52 (10.4)	7.3 - 14.6	
High level of belief	12038 (94.5)	7838 (65.1)	63.5 - 66.7		2077 (17.3)	16.3 - 18.3	
Belief about Malaria				<0.001*			0.242
morbidity							
Low level of belief	1614 (12.7)	912 (56.5)	52.4 - 59.2		240 (14.9)	12.7 – 16.7	
Average level of belief	3869 (30.4)	5400 (62.8)	61.2 - 65.9		648 (16.8)	15.6 - 19.7	
High level of belief	7258 (57.0)	134 (65.5)	63.4 - 67.2		1255 (17.3)	15.8 - 18.2	
ANC: Antenatal Care,		· ·	·	·	·	•	
*potential candidate for the multiple and the multiple an	ltivariable logistic	e regression					

## 328 Factors associated with uptake of at least one IPTp-SP dose

The results indicated that all selected maternal characteristics were independently associated with 329 receiving at least one IPTp-SP dose during pregnancy (Table 4). Yet, after adjusting for other 330 factors in the multivariable model, uptake of at least one IPTp-SP dose was significantly associated 331 332 with pregnant women's age group, the region where they live, and the frequency of ANC visits. Also, women's belief in the effectiveness of SP for malaria treatment and about morbidities caused 333 by malaria influenced their decision to initiate antimalaria treatment during pregnancy. For 334 335 instance, pregnant women aged 35 and above had a 42% higher likelihood of receiving at least the first dose than those aged 15 to 24 (aOR:1.42; 95% CI: 1.12-1.81). Also, women living in the 336 south-west were 50% less likely to receive at least one dose than North-Central (aOR: 0.50; 95%) 337 CI: 0.38 - 0.64). The results also indicated that those with four or more ANC visits had 61% greater 338 odds of taking at least one SP dose than those with fewer ANC attendance (aOR: 1.61; 95% CI: 339 1.36–1.91). The timing of ANC initiation showed no significant association with using at least one 340 IPTp-SP dose (p = 0.138). Those who somewhat believed in the drug's effectiveness were 50% 341 less likely to receive at least a single SP dose than those with a minimal belief (aOR:0.50; 95% CI: 342 343 0.26–1.00). Conversely, the awareness of morbidities caused by malaria during pregnancy predicted a higher uptake of at least one SP dose (p = 0.013). Those with firm beliefs were 33% 344 more likely to receive at least a single IPTp-SP dose than those unaware of malaria-associated 345 346 morbidities (aOR: 1.33; 95% CI: 1.10-1.62). The household wealth index and spouse's educational level interacted significantly with the uptake of at least one SP dose (p=0.048). As a 347 result, women in the wealthiest household whose husbands had secondary education had a four-348 fold higher odds of receiving at least one dose of IPTp-SP than those impoverished with no formal 349 education (aOR:4.17; 95% CI:1.11-8.85). 350

Factors   Total N (%)		Crude OR (95% CI) Uptake of at least one dose	P-value	Adjusted OR (95%CI) Uptake of at least one dose	P-value
Socio-demograph	hic Factors	1	1	1	-
Age in years			<b>0.011</b> <sup><i>a</i></sup>		<b>0.008</b> <i>a</i>
15-24	3,842 (30.2)	1.00		1.00	
25-34	6,242 (49.0)	1.17 (1.06 - 1.29)	0.003	1.10 (0.92 - 1.31)	0.287
35+	2,657 (19.3)	1.12 (0.98 - 1.28)	0.100	1.42 (1.12 - 1.81)	0.004
Region			<b>&lt;0.001</b> <sup><i>a</i></sup>		<b>&lt;0.001</b> <sup>a</sup>
North Central	1,770 (13.9)	1.00		1.00	
North East	2,339 (18.4)	1.42 (1.17 - 1.73)	< 0.001	2.05 (1.63 - 2.59)	< 0.001
North West	4,639 (36.4)	1.08 (0.88 - 1.31)	0.465	2.53 (1.98 - 3.23)	< 0.001
South East	1,263 (9.9)	2.96 (2.36 - 3.71)	< 0.001	1.33 (1.01 - 1.74)	0.039
South South	1,126 (8.8)	2.22 (1.817 - 2.700)	< 0.001	1.61 (1.23 – 2.11)	0.001
South West	1,606 (12.6)	1.34 (1.08 - 1.66)	0.007	0.50 (0.38 - 0.64)	< 0.001
<b>Residential areas</b>	, ,		<b>&lt;0.001</b> <sup><i>a</i></sup>		<b>0.087</b> <sup>a</sup>
Urban	4,854 (38.1)	1.00		1.00	
Rural	7,888 (61.9)	0.52 (0.45 - 0.60)	< 0.001	1.15 (0.98 - 1.36)	0.087
<b>Highest Educatio</b>	onal Level		<b>&lt;0.001</b> <sup>a</sup>		<b>0.854</b> <sup>a</sup>
No Education	5,766 (45.3)	1.00		1.00	
Primary	1,856 (14.6)	2.01 (1.74 - 2.33)	< 0.001	1.01 (0.84 - 1.22)	0.902
Secondary	4,050 (31.8)	2.75 (2.41 - 3.14)	< 0.001	0.94 (0.77 - 1.15)	0.530
Higher	1,070 (8.4)	4.371 (3.53 - 5.42)	< 0.001	0.92 (0.67 - 1.25)	0.585
Household wealt	h Index		<b>&lt;0.001</b> <sup><i>a</i></sup>		<b>0.846</b> <sup><i>a</i></sup>
Poorest	2,763 (21.7)	1.00		1.00	
Poorer	2,933 (23.0)	1.29 (1.10 - 1.51)	0.001	0.93 (0.71 – 1.21)	0.583
Middle	2,636 (20.7)	2.31 (1.97 - 2.72)	< 0.001	1.07 (0.77 – 1.48)	0.698
Richer	2,358 (18.5)	2.98 (2.49 - 3.57)	< 0.001	1.20 (0.69 - 2.08)	0.515
Richest	2,052 (16.1)	4.58 (3.75 - 5.61)	< 0.001	0.94 (0.38 - 2.37)	0.902
<b>Employment Sta</b>	tus		<b>&lt;0.001</b> <sup><i>a</i></sup>		<b>0.693</b> <sup>a</sup>
Not Employed	3,915 (30.7)	1.00		1	
Employed	8,827 (69.3)	1.46 (1.31 - 1.62)	< 0.001	1.03 (0.89 - 1.19)	0.693
Spouse's Educati	ion Level		<b>&lt;0.001</b> <sup><i>a</i></sup>		<b>0.695</b> <sup>a</sup>
No Education	4,568 (35.6)	1.00		1.00	
Primary	1,624 (12.7)	2.09 (1.77 - 2.46)	< 0.001	1.10 (0.66 - 1.82)	0.721
Secondary	4,116 (32.7)	3.07 (2.69 - 3.51)	< 0.001	1.04 (0.70 - 1.51)	0.882
Higher	1,872 (14.7)	4.54 (3.80 - 5.42)	< 0.001	1.95 (0.61 - 6.36)	0.261
Pregnancy-relate	, , ,	· · · · /		· · · · · · · · · · · · · · · · · · ·	1
Frequency of AN			<b>&lt;0.001</b> <sup>a</sup>		<b>&lt;0.001</b> <sup>a</sup>
<4 ANC Visits	2,351 (24.7)	1.00		1.00	
$\geq$ 4 ANC Visits	7,151 (75.3)	1.50 (1.31 - 1.72)	< 0.001	1.61 (1.36 - 1.91)	< 0.001
Timing of ANC I	nitiation		<b>0.001</b> <sup>a</sup>		<b>0.138</b> <i>a</i>

## 351 Table 4: Factors associated with uptake of at least one SP dose among pregnant women

1st Trimester 2,273 (23.6)		1.00		1.00	
2nd Trimester	6,003 (62.3)	0.96 (0.83 - 1.12)	0.631	0.98 (0.83 - 1.15)	0.780
3rd Trimester	1,365 (14.2)	0.71 (0.59 - 0.86)	< 0.001	0.81 (0.65 - 1.02)	0.080
Number of			<b>&lt;0.001</b> <sup><i>a</i></sup>		<b>0.328</b> <i>a</i>
children born					
<4 children	6692 (52.7)	1.00		1.00	
4+ children	6049 (47.5)	0.78 (0.71 – 0.85)	< 0.001	0.92 (0.77 – 1.09)	0.328
Knowledge of ma	laria-related fac	tors			
Media Exposure			<b>&lt;0.001</b> <sup>a</sup>		<b>0.175</b> <sup><i>a</i></sup>
No	11,823 (92.8)	1.00		1.00	
Yes	919 (7.2)	2.69 (2.14 - 3.37)	< 0.001	1.20 (0.92 - 1.56)	0.175
Health Insurance coverage			<b>0.001</b> <sup>a</sup>		<b>0.082</b> <sup>a</sup>
No	12,484 (98.0)	1.00		1.00	
Yes	258 (2.0)	2.51 (1.47 - 4.28)	0.001	1.51 (0.26 - 1.00)	0.053
Belief in Effectiveness of SP			<b>&lt;0.001</b> <sup>a</sup>		<b>&lt;0.001</b> <sup><i>a</i></sup>
Low belief	200 (1.6)	1.00		1.00	
Average belief	504 (4.0)	0.69 (0.47 - 1.03)	0.072	0.50 (0.26 - 1.00)	0.053
High belief	12,038 (94.5)	2.47 (1.81 - 3.38)	< 0.001	1.51 (0.90 - 2.51)	0.116
Belief about Malaria morbidity			<b>&lt;0.001</b> <sup>a</sup>		<b>0.013</b> <i>a</i>
Low belief	1,615 (12.7)	1.00		1.00	
Average belief	3,869 (30.4)	1.38 (1.17 - 1.62)	< 0.001	1.32 (1.05 - 1.67)	0.017
High belief	7,258 (57.0)	1.49 (1.29 - 1.72)	< 0.001	1.33 (1.10 - 1.62)	0.003
ANC – Antenatal	care		- I		

*ANC* – *Antenatal care* 

<sup>*a*</sup>*p*-values – overall *p*-values for each exposure variable in the model, CI – Confidence Intervals OR – Odds ratios, crude OR (from Bivariate analysis) Adjusted OR (from Multivariable analysis) Goodness-of-fit of the model = F(9, 1262) = 0.651; p = 0.754

1 => Reference category

352

## 361 Factors associated with the uptake of optimal doses of IPTp-SP

All included maternal characteristics in the study were independently associated with the uptake 362 of at least three IPTp-SP doses (Table 5). However, after adjusting for all factors in the model, 363 household wealth index, frequency of ANC visits, and ANC initiation were significantly related 364 365 to taking at least three IPTp-SP doses. The result established that compared to women with no formal education, those with higher education were 30% less likely to take at least three SP doses 366 (aOR: 0.70 95% CI:0.51–0.98). In contrast, women whose spouses attained higher education had 367 368 an 85% probability of completing optimal doses than those whose spouses had no formal education (aOR: 1.85; 95% CI: 1.39–2.46). Unexpectedly, the uptake of optimal IPTp-SP doses was 369 370 inversely associated with the household wealth index. Compared to women in most impoverished 371 households, the probability of taking at least three SP doses was reduced by 35% among women in poorer households and middle class (aOR: 0.65; 95% CI:0.52-0.82) and decreased by 29% 372 among wealthiest households (aOR: 0.71; 95% CI: 0.52 - 0.97). Furthermore, the probability of 373 completing at least three doses among pregnant women who attended four or more ANC visits was 374 57% higher than those with fewer ANC visits (aOR: 1.57; 95% CI:1.31 - 1.88). Conversely, the 375 376 timing of initiating ANC services predicted a negative association with taking optimal SP doses during pregnancy (p <0.001). Those who initiated ANC in their third trimester were 39% less 377 likely to complete optimal IPTp-SP doses during pregnancy (aOR:0.61; 95% CI: 0.47-0.79). Also, 378 379 pregnant women exposed to media messages were 1.39 times as likely to complete optimal doses of IPTp-SP than those not exposed to media messages (aOR: 1.39; 95% CI: 1.10 - 1.75). Also, the 380 receipt of optimal doses was associated with the level of belief about morbidity caused by malaria 381 (p = 0.021). In contrast, the belief level in the effectiveness of SP against malaria in pregnancy did 382 not play a role in taking IPTp-SP (p=0.102) 383

Factors	Total N (%)	Crude OR (95% CI) Uptake of optimal doses	p-value	Adjusted OR (95% CI) Uptake of optimal doses	p-value
Sociodemograp	hic factors	e pune of optimit doses		optante of optimal acises	
Age in years			<b>0.015</b> <sup><i>a</i></sup>		<b>0.583</b> <sup>a</sup>
15-24	3,842 (30.2)	1.00		1.00	
25-34	6,242 (49.0)	1.21 (1.06 - 1.38)	0.004	1.07 (0.90 - 1.27)	0.420
35+	2,462 (19.3)	1.19 (1.01 - 1.40)	0.036	1.14 (0.89 - 1.46)	0.300
Region			<b>&lt;0.001</b> <sup><i>a</i></sup>		<b>&lt;0.001</b> <sup><i>a</i></sup>
North Central	1,770 (13.9)	1.00		1.00	
North East	2,339 (18.4)	0.93 (0.74 - 1.18)	0.558	0.90 (0.70 - 1.15)	0.116
North West	4,639 (36.4)	0.69 (0.56 - 0.86)	0.001	0.97 (0.76 - 1.24)	0.475
South East	1,263 (9.9)	3.65 (2.98 - 4.48)	< 0.001	2.96 (2.31 - 3.80)	0.187
South South	1,126 (8.8)	1.84 (1.48 - 2.30)	< 0.001	1.58 (1.20 - 2.06)	< 0.001
South West	1,606 (12.6)	1.20 (0.28 - 1.55)	0.166	0.82 (0.63 - 1.06)	< 0.001
Residential areas			<0.001 <sup>a</sup>		<b>0.240</b> <sup>a</sup>
Urban	4,854 (38.1)	1.00		1.00	
Rural	7,888 (61.9)	0.61 (0.53 - 0.70)	< 0.001	1.11 (0.93 - 1.31)	0.240
Highest Educati	ional Level		<b>&lt;0.001</b> <sup><i>a</i></sup>		<b>0.168</b> <sup>a</sup>
No Education	5,766 (45.3)	1.00		1.00	
Primary	1,856 (14.6)	1.94 (1.63 - 2.31)	< 0.001	0.97 (0.80 - 1.17)	0.749
Secondary	4,050 (31.8)	2.61 (2.25 - 3.04)	< 0.001	0.85 (0.68 - 1.03)	0.115
Higher	1,070 (8.4)	2.89 (2.31 - 3.62)	< 0.001	0.70 (0.51 - 0.98)	0.035
Household Wealth Index			<b>&lt;0.001</b> <sup><i>a</i></sup>		<b>0.003</b> <sup>a</sup>
Poorest	2,763 (21.7)	1.00		1.00	
Poorer	2,933 (23.0)	0.90 (0.72 - 1.11)	0.326	0.65 (0.52 - 0.82)	< 0.001
Middle	2,636 (20.7)	1.38 (1.12 - 1.71)	0.003	0.65 (0.51 - 0.82)	< 0.001
Richer	2,358 (18.5)	2.20 (1.78 - 2.73)	< 0.001	0.82 (0.65 - 1.04)	0.088
Richest	2,052 (16.1)	2.41 (1.93 - 2.30)	< 0.001	0.71 (0.52 - 0.97)	0.027
Employment Status			<b>&lt;0.001</b> <sup><i>a</i></sup>		<b>0.668</b> <sup><i>a</i></sup>
Not Employed	3,915 (30.7)	1.00		1.00	
Employed	8,827 (69.3)	1.39 (1.21 - 1.60)	< 0.001	0.97 (0.82 - 1.13)	0.668
Spouse's Educa	tional Level		<b>&lt;0.001</b> <sup><i>a</i></sup>		<b>&lt;0.001</b> <sup>a</sup>
No Education	4,568 (35.6)	1.00		1.00	
Primary	1,624 (12.7)	1.92 (1.55 - 2.39)	< 0.001	1.06 (0.84 - 1.34)	0.611
Secondary 4,116 (32.7)		3.30 (2.76 - 3.93)	< 0.001	1.70 (1.39 - 2.08)	< 0.001
Higher	1,872 (14.7)	3.19 (2.568 - 3.961)	< 0.001	1.85 (1.39 - 2.46)	< 0.001
Pregnancy-relat	ted factors				
Frequency of A	-		<b>&lt;0.001</b> <sup><i>a</i></sup>		<b>&lt;0.001</b> <sup><i>a</i></sup>
<4 ANC Visits	2,351 (24.7)	1.00		1.00	

# Table 5: Factors associated with uptake of optimal doses of IPTp-SP among pregnant women

≥4 ANC Visits	7,151 (75.3)	2.10 (1.79 - 2.47)	< 0.001	1.57 (1.31 - 1.88)	< 0.001
Timing of ANC	Initiation		<b>&lt;0.001</b> <sup>a</sup>		<b>&lt;0.001</b> <sup>a</sup>
1st Trimester	2,273 (23.6)	1.00		1.00	
2nd Trimester	6,003 (62.3)	0.62 (0.54 - 0.71)	< 0.001	0.71 (0.61 - 0.82)	< 0.001
3rd Trimester	1,365 (14.2)	0.40 (0.32 - 0.50)	< 0.001	0.61 (0.47 - 0.79)	< 0.001
Number of			<b>&lt;0.001</b> <sup><i>a</i></sup>		<b>0.681</b> <sup>a</sup>
children born					
<4 children	6692 (52.7)	1.00		1.00	
4+ children	6049 (47.5)	0.80 (0.72 - 0.89)	< 0.001	0.96 (0.81 – 1.14)	0.681
Knowledge of m	alaria-related fa	actors			
Media			<b>&lt;0.001</b> <sup><i>a</i></sup>		<b>0.007</b> <sup>a</sup>
Exposure					
No	11,823 (92.8)	1.00		1.00	
Yes	919 (7.2)	2.45 (1.96 - 3.07)	< 0.001	1.38 (1.10 - 1.75)	0.007
Health Insurance coverage			<b>&lt;0.001</b> <sup>a</sup>		<b>0.076</b> <sup>a</sup>
No	12,484 (98.0)	1.00		1.00	
Yes	258 (2.0)	1.94 (1.41 - 2.66)	< 0.001	1.37 (0.97 - 1.94)	0.076
Belief in Effectiveness of SP			<b>&lt;0.001</b> <sup>a</sup>		<b>0.102</b> <sup>a</sup>
Low	200 (1.6)	1.00		1.00	
Average	504 (4.0)	1.49 (0.78 - 2.85)	0.223	1.17 (0.54 - 2.55)	0.694
High	12,038 (94.5)	2.68 (1.62 - 4.44)	< 0.001	1.63 (0.92 - 2.88)	0.093
Belief about Malaria			<b>0.074</b> <sup>a</sup>		<b>0.021</b> <sup>a</sup>
morbidity					
Low	1,615 (12.7)	1.00		1.00	
Average	3,869 (30.4)	1.25 (1.01 - 1.54)	0.037	1.14 (0.91 - 1.42)	0.250
High	7,258 (57.0)	1.20 (1.01 - 1.43)	0.041	0.90 (0.73 - 1.10)	0.305

uptake of optimal doses of IPTp-SP implies uptake of at least three doses of IPTp-SP; ANC – Antenatal care

<sup>*a*</sup>*p*-values – overall *p*-values for each exposure variable in the model, CI – Confidence Intervals OR – Odds ratios, crude OR (from Bivariate analysis), Adjusted OR (from Multivariable analysis) Goodness-of-fit of the model = F(9, 1262) = 0.222; p = 0.991

1 => Reference category

386

# 388 **Discussion**

This study established the prevalence of IPTp-SP and the factors associated with the uptake of at least one dose and at least three doses of IPTp-SP among pregnant women in Nigeria. The study found a low and regional disparities in prevalence of IPTp-SP uptake during pregnancy. Several maternal characteristics such as, age group, education, antenatal care attendance, household wealth index and spouse's educational attainment were found to contribute to the low IPTp-SP uptake during pregnancy in Nigeria.

In this study, compared with at least one SP dose at 63.6%, the prevalence of three or more SP 395 doses was much lower at 16.8% among pregnant women in Nigeria. These findings fall 396 significantly below the National Malaria Elimination Programme's stipulated target for 100% of 397 pregnant women attending ANC in Nigeria to receive at least three IPTp-SP doses by 2020 (24). 398 A similar low prevalence of at least one dose at 62% and three or more IPTp-SP doses at 32% 399 400 across sub-Saharan African countries were reported in the WHO malaria report in 2019 (1). According Hill et al., 2013, differences in maternal characteristics across and within countries in 401 402 sub-Saharan Africa contributed to low IPTp-SP prevalence of IPTp-SP (8). Also, Pons-Duran et 403 al., 2020 reported that the prevalence of taking optimal IPTp-SP doses was significantly below 25% in DR Congo, Madagascar and Nigeria (10). Conversely, the literature revealed the 404 prevalence of IPTp-SP uptake is somewhat higher at 46%, 63% and 42% in Uganda (25), Ghana 405 406 (13), and Malawi (26), respectively.

407 Several sociodemographic characteristics were established as factors associated with the uptake 408 of at least one IPTp-SP dose. In terms of age group, women aged 35 years and above had higher 409 odds of receiving at least one IPTp-SP dose during pregnancy. This finding was consistent with

410 Olugbade et al., 2019 in Nigeria (27) and Kibusi et al., 2015 in Tanzania (28). The higher uptake of at least one dose among older women may be attributed to earlier exposure to the benefit of 411 IPTp-SP during prior pregnancies (29). In contrast, pregnant women's age group did not play a 412 significant role in taking optimal antimalarial regimens, as supported by Hill et al., 2013 (8). 413 Women residing in Northern Nigeria had the highest likelihood of taking at least one IPTp-SP 414 415 dose due to a noticeable influence of Non-governmental Organisations in supporting increase access to healthcare interventions in the region (30). This regional variation in the level of IPTp-416 SP is consistent in other sub-Saharan African countries (8). This evidence may be due to inequality 417 418 in accessing care in Nigeria, as Olukoya and Adebiyi reported in 2017 (23).

The finding agrees with Yaya et al., 2018, who found that pregnant women's educational status in 419 420 malaria-endemic countries negatively predicted optimal IPTp-SP doses (12). The result suggests that level of education can contribute to poor adherence to receiving optimal antimalarial regimens 421 during pregnancy. The opposite is accurate regarding the association between uptake of IPTp-SP 422 and the spouse's educational level. The current findings agree with studies conducted in Eastern 423 Nigeria (31). The findings infer that male involvement in ANC services during pregnancy might 424 425 predict a higher IPTp-SP uptake (32). Utilising at least one dose and optimal IPTp-SP doses are 426 associated with the household wealth index in different directions. Previous studies established a positive association between receiving optimal IPTp-SP doses and the household's wealth index 427 428 (10,11). However, this current study found that pregnant women have reduced odds of receiving 429 the optimal doses of IPTp-SP regardless of their wealth index. Conversely, Muhammed et al., 2020 found that pregnant women from the wealthiest households have increased IPTp-SP uptake than 430 those from the poorest households in Nigeria (11). The disparity in the results may be attributed to 431 432 the different methodologies adopted in assessing the association between wealth index and uptake

of IPTp-SP. The current study reported that 84.3% of pregnant women who did not receive the
optimal doses of IPTp-SP were also not exposed to media messages. The results may be a plausible
reason for the wealth index indirectly influencing the uptake of optimal doses of IPTp-SP in this
study. Regardless of the wealth index, studies support the evidence that knowledge of malariarelated interventions may affect adherence to completing three or more IPTp-SP doses during
pregnancy (8,15)

Early commencement of ANC services (timing of ANC initiation) implied an increased likelihood 439 of initiating the first dose and completing at least three IPTp-SP doses during pregnancy. This 440 finding aligns with the new IPTp-SP policy, which recommends the uptake of the first IPTp-SP 441 dose after the first trimester during pregnancy and then successive IPTp-SP doses received in each 442 443 scheduled ANC visit at a one-month interval (5). Studies conducted in Tanzania (16), Uganda (25), Malawi (33), and Nigeria (11) established similar findings. Also, ANC attendance was 444 significantly associated with IPTp-SP uptake, as supported by Hill et al., 2013, a study conducted 445 in SSA countries, including Nigeria (8). Among the study participants who visited the ANC clinic 446 at least four times during pregnancy in 2018, approximately 84% of them initiated ANC services 447 in their second trimester. Yet, only 23.3% received three or more IPTp-SP doses, though 80.3% 448 received at least the first SP dose during pregnancy. This evidence implies lost opportunities to 449 deliver the optimal IPTp-SP doses to pregnant women who visited ANC clinics at least four times. 450 451 Even though the WHO recommends delivering IPTp-SP via scheduled ANC services to pregnant 452 women living in malaria-endemic countries, the findings in Nigeria suggest otherwise. As evident in previous studies, the low IPTp-SP uptake via the ANC platform may be attributed to identified 453 healthcare system constraints such as non-compliance to IPTp-SP guidelines (34), a shortage of 454

trained healthcare workers (35), occasional SP stock-out (34,35) and inadequate knowledge or
awareness about IPTp-SP guidelines (36).

457 The finding suggests that exposure to malaria-related messages at least once a week may increase 458 the odds of being aware of the benefits of IPTp-SP during pregnancy. This increased awareness may translate to higher chances of taking three or more IPTp-SP doses by pregnant women. Similar 459 460 results have been found in Ghana (13), Uganda (25) and Tanzania (16). Furthermore, among pregnant, there was a direct association between taking IPTp-SP and their belief in its effectiveness 461 462 against malaria infection. Such that their level of belief may explain their level of trust in the efficacy and safety of IPTp-SP. In this study, the findings suggest that women with less belief in 463 the effectiveness of IPTp-SP were less likely to initiate IPTp-SP use than those with firm belief. 464 This finding aligns with Balami et al., 2020, that knowledge about the efficacy of SP predicts the 465 receipt of the first SP dose. And ultimately, the subsequent IPTp-SP doses during pregnancy (37). 466 Also, pregnant women's awareness of the morbidity caused by malaria predicted higher uptake of 467 468 at least one SP dose but not optimal doses received. In agreement with the finding, Arnaldo et al., 2019 found that a lack of awareness of malaria-associated morbidity reduced the odds of taking 469 470 SP by pregnant women in Mozambique (38). These findings reiterate the need to utilise social and 471 behaviour change communication strategies to drive IPTp-SP uptake at the community level. Meanwhile, there was no significant association among women who subscribed to health insurance 472 473 and IPTp-SP uptake during pregnancy. In contrast, Darteh et al., 2020 found an increased IPTp-474 SP uptake among women with health insurance coverage in Ghana (13). The difference in findings may be because only 2% of study participants were covered by health insurance in Nigeria 475 compared to the study in Ghana where about 48% of study participants were covered by health 476 insurance (13). 477

478 The major strength of this study was using a nationally representative sample to establish the factors related to IPTp-SP uptake. Next, the sample used was considerably large (n=12,742). 479 Therefore, the findings may be generalisable to Nigerian women with live births on the factors that 480 may influence the effective delivery of IPTp-SP during pregnancy. However, it is essential to note 481 the following limitations in considering the factors associated with IPTp-SP use among women 482 483 with live births in Nigeria. First, the established factors associated with IPTp-SP use do not imply causality because of the cross-sectional nature of the study design. Secondly, this study could not 484 assess pregnant women's attitudes and healthcare-related constraints concerning IPTp-SP use 485 486 because the analysis was limited to the variables in the 2018 NDHS questionnaire. Therefore, there is a likelihood that women who attended at least four ANC visits during pregnancy did not receive 487 IPTp-SP because of a stock-out of the drug. Third, excluding women who had stillbirths may have 488 489 resulted in selection bias. The exclusion might have reduced the estimated effect of each possible factor on the uptake of IPTp-SP (39). Fourth, as a self-reported survey, the study is liable to social 490 desirability bias as the women's self-reported responses might not reflect the reality of the issues. 491 Lastly, recall bias is an inherent limitation of survey designs resulting in varying degrees of 492 accuracy in their previous experiences. However, some recall biases were minimised by including 493 only women with live births during or two years before the Nigeria Demographic Health Survey 494 in 2018. 495

## 496 Conclusion

There is low uptake of at least one IPTp-SP dose and even lower uptake of three or more doses by pregnant women in Nigeria. This low uptake of IPTp-SP was associated with several maternal characteristics, age group, education, antenatal care attendance, household wealth index and trust in the efficacy and safety of SP. Therefore, there is a need for context-specific strategies such as

501 targeted mass sensitisation and community awareness to increase the coverage of IPTp-SP uptake 502 among vulnerable women. In addition, future research should explore the drivers of region-specific 503 low uptake of optimal doses among pregnant women, especially in South-West Nigeria. IPTp-SP 504 uptake remains suboptimal despite a relatively high antenatal care attendance among pregnant women in Nigeria. This situation calls for urgent action to deploy region-specific strategies to 505 506 mitigate the bottlenecks (such as drug stock-out and non-compliance to the guidelines) at the 507 healthcare facilities that hinder the delivery of IPTp-SP via ANC clinics in Nigeria. Also, pregnant women's belief in the effectiveness of IPTp-SP influences their decision to initiate antimalarial 508 509 treatment. Therefore, future research should examine the effectiveness of social-behavioural change communication strategies in driving uptake of three or more IPTp-SP doses during 510 511 pregnancy in Nigeria.

512

513

514

515

516

517

# 519 Acknowledgement

- 520 We are grateful to Measure DHS for the permission and for providing me with the dataset for this
- study. The authors also would like to thank the University of the Witwatersrand Human Research
- 522 Ethics Committee (Medical) for the ethical approval.

# 523 Authors contribution

- 524 Conceptualisation: Godwin Okeke Kalu, Joel Msafiri Francis, Juliana Kagura, Latifat Ibisomi
- 525 Data curation: Godwin Okeke Kalu
- 526 Formal analysis: Godwin Okeke Kalu, Joel Msafiri Francis, Juliana Kagura
- 527 Methodology: Godwin Okeke Kalu, Joel Msafiri Francis, Juliana Kagura, Latifat Ibisomi,
- 528 Tobias Chirwa
- 529 Funding Acquisition: Latifat Ibisomi, Tobias Chirwa
- 530 Project administration: Godwin Okeke Kalu, Joel Msafiri Francis, Juliana Kagura
- 531 Supervision: Joel Msafiri Francis, Juliana Kagura
- 532 Validation: Godwin Okeke Kalu, Joel Msafiri Francis, Juliana Kagura
- 533 Visualisation: Godwin Okeke Kalu, Joel Msafiri Francis, Juliana Kagura
- 534 Writing- original draft preparation: Godwin Okeke Kalu
- Writing- review and editing: Godwin Okeke Kalu, Joel Msafiri Francis, Juliana Kagura, Latifat
  Ibisomi, Tobias Chirwa
- 537

# 538 Funding

- 539 TDR supported this research work as part of the Special Programme for Research and Training in
- 540 Tropical Diseases (TDR). TDR is hosted by the World Health Organization and co-sponsored by
- 541 UNICEF, UNDP, the World Bank and WHO. The TDR grant number: B40299. The funders did

not play a role in the study design, data collection and analysis, decision to publish or preparationof the manuscript.

# 544 **Competing interests**

545 The authors have declared no competing interests exist.

546

# 547 Availability of data and materials

548	The dataset for the study was obtained with permission from the Demographic and Health Surveys
549	(DHS) Program. The dataset are publicly available and may be requested from the DHS Program
550	office via https://www.dhsprogram.com/data/dataset_admin/. The questionnaire used for the
551	analyses is the women's questionnaire contained within the 2018 NDHS, which can be accessed
552	via https://www.dhsprogram.com/publications/publication-FR359-DHS-FinalReports.cfm.
553	
554	
555	
556	
557	
558	
559	

# 560 **References**

- World Health Organization. World Malaria Report: 20 years of global progress and challenges. World Health Organization. 2020.
- World Health Organization. World malaria report 2019 [Internet]. 2019. Available from: https://www.who.int/publications/i/item/world-malaria-report-2019
- 3. Rogerson SJ, Desai M, Mayor A, Sicuri E, Taylor SM, van Eijk AM. Burden, pathology,
  and costs of malaria in pregnancy: new developments for an old problem. Vol. 18, The
  Lancet Infectious Diseases. Lancet Publishing Group; 2018. p. e107–18.
- Rogerson SJ, Hviid L, Duffy PE, Leke RF, Taylor DW. Malaria in pregnancy:
   pathogenesis and immunity. Vol. 7, Lancet Infectious Diseases. Elsevier; 2007. p. 105–17.
- 5. WHO Global Malaria Programme. New WHO recommendations for IPTp-SP [Internet].
  2013 [cited 2021 Feb 8]. Available from: http://whqlibdoc.who.int/publications/2010/9789241599412 eng.pdf
- Kayentao K, Garner P, Van Eijk AM, Naidoo I, Roper C, Mulokozi A, et al. Intermittent
  preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of
  sulfadoxine-pyrimethamine and risk of low birth weight in Africa: Systematic review and
  meta-analysis. Vol. 309, JAMA Journal of the American Medical Association. JAMA;
  2013. p. 594–604.
- 578 7. Lawn JE, Blencowe H, Waiswa P, Amouzou A, Mathers C, Hogan D, et al. Stillbirths:
  579 Rates, risk factors, and acceleration towards 2030. Vol. 387, The Lancet. 2016. p. 587–
  580 603.
- 8. Hill J, Hoyt J, van Eijk AM, D'Mello-Guyett L, ter Kuile FO, Steketee R, et al. Factors
   Affecting the Delivery, Access, and Use of Interventions to Prevent Malaria in Pregnancy
   in Sub-Saharan Africa: A Systematic Review and Meta-Analysis. Noor AM, editor. PLoS
   Medicine. 2013 Jul 23;10(7):e1001488.
- Balami AD, Said SM, Zulkefli NAM, Bachok N, Audu B. Effects of a health educational intervention on malaria knowledge, motivation, and behavioural skills: A randomized controlled trial PACTR201610001823405 PACTR. Malaria Journal. 2019;18(1):1–14.
- Pons-Duran C, Llach M, Sacoor C, Sanz S, Macete E, Arikpo I, et al. Coverage of
  intermittent preventive treatment of malaria in pregnancy in four sub-Saharan countries:
  findings from household surveys. International Journal of Epidemiology. 2020;1–10.
- Muhammad FM, Majdzadeh R, Nedjat S, Sajadi HS, Parsaeian M. Socioeconomic
   inequality in intermittent preventive treatment using Sulphadoxine pyrimethamine among
   pregnant women in Nigeria. BMC Public Health. 2020;20(1):1–9.
- Yaya S, Uthman OA, Amouzou A, Bishwajit G. Use of intermittent preventive treatment
   among pregnant women in sub-Saharan Africa: Evidence from malaria indicator surveys.
   Tropical Medicine and Infectious Disease. 2018;3(1).
- 597 13. Darteh EKM, Buabeng I, Akuamoah-Boateng C. Uptake of intermittent preventive


598		treatment in pregnancy for malaria: further analysis of the 2016 Ghana Malaria Indicator
599		Survey. Journal of Public Health (Germany). 2020;
600 601 602	14.	Olukoya OO, Adebiyi OA. Missed Opportunities for Intermittent Preventive Treatment for Malaria in Pregnancy in Nigeria: Evidence From Demographic and Health Survey in Nigeria 2013. Annals of Ibadan postgraduate medicine. 2017;15(2):88–95.
603 604 605 606	15.	Mchwampaka WM, Tarimo D, Chacky F, Mohamed A, Kishimba R, Samwel A. Factors affecting uptake of $\geq$ 3 doses of Sulfadoxine-Pyrimethamine for malaria prevention in pregnancy in selected health facilities, Arusha region, Tanzania. BMC Pregnancy and Childbirth. 2019 Nov 27;19(1).
607 608 609 610	16.	Exavery A, Mbaruku G, Mbuyita S, Makemba A, Kinyonge IP, Kweka H. Factors affecting uptake of optimal doses of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy in six districts of Tanzania. Malaria Journal. 2014 Jan 14;13(1).
611 612 613	17.	Ndu A, Mbachu C, Anitube O, Ezeoke U. Inequities in the use of sulphadoxine- pyrimethamine for malaria prophylaxis during pregnancy in Nigeria. Malawi Medical Journal. 2020;32(1):45–51.
614 615 616	18.	Rassi C, Graham K, King R, Ssekitooleko J, Mufubenga P, Gudoi SS. Assessing demand- side barriers to uptake of intermittent preventive treatment for malaria in pregnancy: a qualitative study in two regions of Uganda. Malaria Journal. 2016;15(1):1–14.
617 618	19.	NPC, ICF. The Federal Republic of Nigeria Nigeria Demographic and Health Survey 2018 National Population Commission Abuja, Nigeria. 2019.
619 620 621	20.	Chukwu C, Onuoha H, Adline Katty Okorafor K, Ojomo O, Mokuolu OA, Ekholuenetale MI. Geopolitical zones differentials in intermittent preventive treatment in pregnancy (IPTp) and long lasting insecticidal nets (LLIN) utilization in Nigeria. 2021;
622 623 624 625	21.	Oppong FB, Gyaase S, Zandoh C, Nettey OEA, Amenga-Etego S, Anane EA, et al. Intermittent preventive treatment of pregnant women in Kintampo area of Ghana with sulphadoxine-pyrimethamine (SP): Trends spanning 2011 and 2015. BMJ Open. 2019;9(6).
626 627 628	22.	Okafor I, Ezekude C, Oluwole E, Onigbogi O. Malaria in pregnancy: A community-based study on the knowledge, perception, and prevention among Nigerian women. Journal of Family Medicine and Primary Care. 2019;8(4):1359.
629 630 631	23.	StataCorp. 2019. Stata Statistical Software: Release 16. College Station TSL. Stata   StataCorp LLC [Internet]. [cited 2021 Apr 12]. Available from: https://www.stata.com/company/
632 633	24.	Fidock DA. Eliminating malaria [Internet]. Vol. 340, Science. 2013 [cited 2021 Nov 22]. p. 1531–3. Available from: http://www.who.int
634 635 636 637	25.	Okethwangu D, Opigo J, Atugonza S, Kizza CT, Nabatanzi M, Biribawa C, et al. Factors associated with uptake of optimal doses of intermittent preventive treatment for malaria among pregnant women in Uganda: Analysis of data from the Uganda Demographic and Health Survey, 2016. Malaria Journal. 2019 Jul 26;18(1):250.

Azizi SC. Uptake of intermittent preventive treatment for malaria during pregnancy with
Sulphadoxine-Pyrimethamine in Malawi after adoption of updated World Health
Organization policy: An analysis of demographic and health survey 2015-2016. BMC
Public Health. 2020 Mar 16;20(1).

- 642 27. Olugbade OT, Ilesanmi OS, Gubio AB, Ajayi I, Nguku PM, Ajumobi O. Socio643 demographic and regional disparities in utilization of intermittent preventive treatment for
  644 malaria in pregnancy Nigeria demographic health survey 2013. The Pan African medical
  645 journal. 2019;32:13.
- Kibusi SM, Kimunai E, Hines CS. Predictors for uptake of intermittent preventive
  treatment of malaria in pregnancy (IPTp) in Tanzania. 2015;
- Wanzira H, Katamba H, Okullo AE, Rubahika D. The challenge of using intermittent
  preventive therapy with sulfadoxine/pyrimethamine among pregnant women in Uganda.
  Malaria Journal. 2016;15(1):1–7.
- 30. Sanadgol A, Doshmangir L, Majdzadeh R, Gordeev VS. Engagement of nongovernmental organisations in moving towards universal health coverage: a scoping
  review. Globalization and Health. 2021 Dec 1;17(1).
- Akpa CO, Akinyemi JO, Umeokonkwo CD, Bamgboye EA, Dahiru T, Adebowale AS, et
  al. Uptake of intermittent preventive treatment for malaria in pregnancy among women in
  selected communities of Ebonyi State, Nigeria. BMC Pregnancy and Childbirth.
  2019;19(1):1–7.
- Oguntunde O, Nyenwa J, Yusuf FM, Dauda DS, Salihu A, Sinai I. The experience of men
  who participated in interventions to improve demand for and utilization of maternal and
  child health services in northern Nigeria: A qualitative comparative study. Reproductive
  Health. 2019;16(1):1–9.
- 33. Nkoka O, Chuang TW, Chen YH. Association between timing and number of antenatal
  care visits on uptake of intermittent preventive treatment for malaria during pregnancy
  among Malawian women. Malaria Journal. 2018;17(1):1–11.
- 66534.Mchwampaka WM, Tarimo D, Chacky F, Mohamed A, Kishimba R, Samwel A. Factors666affecting uptake of  $\geq$  3 doses of Sulfadoxine-Pyrimethamine for malaria prevention in667pregnancy in selected health facilities, Arusha region, Tanzania. BMC Pregnancy and668Childbirth. 2019;19(1):1–8.
- 35. Okello G, Gerrets R, Zakayo S, Molyneux S, Jones C. "Every day they keep adding new tools but they don't take any away": Producing indicators for intermittent preventive treatment for malaria in pregnancy (IPTp) from routine data in Kenya. PLoS ONE.
  2018;13(1):1–14.
- 673 36. Hurley EA, Harvey SA, Rao N, Diarra NH, Klein MC, Diop SI, et al. Underreporting and
  674 missed opportunities for uptake of intermittent preventative treatment of malaria in
  675 pregnancy (IPTp) in Mali. PLoS ONE. 2016;11(8):1–17.
- Balami AD, Md. Said S, Nor NA, Bachok N, Audu B. Determinants of uptake of first
  dose of intermittent preventive treatment among pregnant women in a secondary health

678		Centre in Maiduguri, Nigeria. BMC Pregnancy and Childbirth. 2020;20(1):1-9.
679 680 681 682	38.	Arnaldo P, Cambe MI, Magaço A, Chicumbe S, Rovira-Vallbona E, Rosanas-Urgell A, et al. Access to and use of preventive intermittent treatment for Malaria during pregnancy: A qualitative study in the Chókwè district, Southern Mozambique. PLoS ONE. 2019;14(1):1–12.
683 684 685	39.	Moore KA, Simpson JA, Scoullar MJL, McGready R, Fowkes FJI. Quantification of the association between malaria in pregnancy and stillbirth: a systematic review and meta- analysis. The Lancet Global Health. 2017 Nov 1;5(11):e1101–12.
686		
687		
688		
689		
690	S	Supporting information
691	S1 Ta	ble. Interaction term between Household wealth Index and Spouse's Educational level.
692	This i	s the extension of Table 4 with interaction term
693	S2 Ta	able. Full multivariable logistic regression for the uptake of at least one IPTp-SP dose
694	(Tabl	e 4). This is the STATA output for the final model (Table 4)
695	S3 Ta	able. Full multivariable logistic regression for uptake of at least three IPTp-SP doses.
696	This i	s the STATA output for the final model (Table 5)
697	S4 Ta	able. The model without interaction term for the uptake of at least one IPTp-SP dose.
698	This i	s the initial model without the interaction for factors associated with at least one SP dose.
699	S5 Ta	able. The model without interaction term for the uptake of at least one IPTp-SP dose.
700	This i	s the STATA output for the initial model without interaction term

- 702
- 703
- 704
- 705



# Figure